GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
GSK's pe ratio was 13.5× on Oct 19, 2026, against 28.7× a year earlier. Over the last 5 years it ranged from 3.7× to 35.3×, with a median of 13.4×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Oct 19, 2026 | 13.5× | −15.8 |
| 2025 | Dec 31, 2025 | 29.3× | +18.1 |
| 2024 | Dec 31, 2024 | 11.3× | +7.3 |
| 2023 | Dec 29, 2023 | 4.0× | −9.5 |
| 2022 | Dec 30, 2022 | 13.4× | −0.6 |
| 2021 | Dec 31, 2021 | 14.0× | −0.2 |
| 2020 | Dec 31, 2020 | 14.3× | −9.6 |
| 2019 | Dec 31, 2019 | 23.8× | −23.5 |
| 2018 | Dec 31, 2018 | 47.4× | −21.8 |
| 2017 | Dec 29, 2017 | 69.1× | +60.2 |
| 2016 | Dec 30, 2016 | 8.9× | – |